Latest News & Features
Big Pharma
Teva’s patents protecting migraine drug ruled invalid | Lilly’s motion for a new trial denied | ‘The court does not reach this decision nor overturn a jury verdict lightly’ says Judge Alison Burroughs. 28 September 2023
Big Pharma
A Federal Circuit decision provides lessons on why inaction over patent terms may risk incurable invalidation of important patents, writes Vincent Shier of Haynes Boone. 28 September 2023
Big Pharma
ANDA litigation expert brings chemical, biotech, and pharmaceutical experience to the firm. 26 September 2023
Americas
Agreement reached over intranasal ketamine royalties and patents | Yale and a professor agree to pay $1.5m to the US government and give up royalty rights. 26 September 2023
Big Pharma
An updated UPC rule requires a concrete and verifiable, legitimate reason for making available written pleadings and evidence | The wish from a natural person to form an opinion on the validity of a patent deemed insufficient reason for access | First decision marks latest twist in Amgen v Sanofi showdown. 26 September 2023
Biotechnology
The spatial biology firm will appeal the Unified Patent Court’s preliminary injunction | NanoString accuses 10x of ‘misusing non-final court rulings…to eliminate competition in the spatial transcriptomics market’. 21 September 2023
Americas
Long-running legal dispute tackles questions of enablement and ‘undue experimentation’ | Federal Circuit says it is bound by SCOTUS’ findings in Amgen v Sanofi. 21 September 2023
Biotechnology
Decision marks first announcement by the UPC of an injunction in open court | Ruling in Munich Local Division forecast to have far-reaching consequences for defendant| Comment from 10x vice president of IP and litigation, Randy Wu. 19 September 2023
Big Pharma
Moderna alleges that rivals’ vaccine infringes patents filed covering a foundational mRNA technology | Big pharma firm must “specifically describe” awareness of Moderna's work in the mRNA vaccine sphere before the end of the month. 19 September 2023
Big Pharma
Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents. 19 September 2023